Copyright
©The Author(s) 2023.
World J Hepatol. Aug 27, 2023; 15(8): 973-984
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.973
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.973
Total (%) | PCR-HCV collection | P value | Specialized assistance | P value | Treatment | P value | SVR | P value | |
Total | 709 | 534 (75.3%) | 461 (65.0%) | 344 (48.5%) | 204 (28.7%) | ||||
Gender | |||||||||
Female | 324 (45.7%) | 238 (73.5%); 0.95 (0.87-1.04) | 0.295 | 221 (68.2%); 1.09 (0.98-1.21) | 0.101 | 175 (54.0%); 1.23 (1.05-1.43) | 0.007 | 109 (62.3%); 1.10 (0.92-1.32) | 0.253 |
Male | 385 (54.3%) | 296 (76.9%); 1.0 | 240 (62.3%); 1.0 | 169 (43.9%); 1.0 | 95 (56.2%); 1.0 | ||||
Age (yr) | |||||||||
17-39 | 118 (16.6%) | 90 (76.3%); 1.0 | 79 (66.9%); 1.0 | 0.420 | 52 (44.1%); 1.0 | 27 (51.9%); 1.0 | |||
40-59 | 348 (49.1%) | 267 (76.7%); 1.00 (0.89-1.13) | 0.920 | 225 (64.7%); 0.96 (0.83-1.12) | 0.646 | 170 (48.9%); 1.10 (0.88-1.39) | 0.380 | 103 (60.6%); 1.16 (0.87-1.55) | 0.294 |
> 60 | 243 (34.3%) | 177 (72.8%); 0.95 (0.84-1.08) | 0.479 | 157 (64.6%); 0.96 (0.82-1.12) | 0.657 | 122 (50.2%); 1.13 (0.89-1.44) | 0.284 | 74 (60.7%); 1.16 (0.86-1.57) | 0.307 |
Race | |||||||||
White | 543 (76.6%) | 405 (74.6%); 1.0 | 353 (65.0%); 1.0 | 269 (49.5%); 1.0 | 164 (61.0%); 1.0 | ||||
Non-white | 154 (21.7%) | 118 (76.6 %); 1.02 (0.92-1.13) | 0.598 | 97 (63.0%); 0.96 (0.84-1.11) | 0.649 | 65 (42.2%); 0.85 (0.69-1.04) | 0.123 | 32 (49.2%); 0.80 (0.62-1.05) | 0.113 |
Education | |||||||||
Illiterate | 39 (5.5%) | 28 (71.8%); 0.88 (0.71-1.08) | 0.238 | 26 (66.7%); 0.95 (0.74-1.22) | 0.741 | 20 (51.3%); 0.96 (0.68-1.35) | 0.834 | 13 (65.0%); 0.95 (0.66-1.36) | 0.804 |
Elementary school | 478 (67.4%) | 344 (72%); 0.88 (0.80-0.97) | 0.011 | 301 (63.0%); 0.90 (0.79-1.03) | 0.134 | 219 (45.8%); 0.86 (0.71-1.03) | 0.110 | 120 (54.8%); 0.80 (0.66-0.98) | 0.031 |
High school and university | 141 (19.9%) | 115 (81.6%); 1.0 | 98 (69.5%); 1.0 | 75 (53.2%); 1.0 | 51 (68.0%); 1.0 | ||||
City of origin | |||||||||
Porto Alegre | 317 (44.7%) | 215 (67.8%); 1.0 | 174 (54.9%); 1.0 | 121 (38.2%); 1.0 | 49 (40.5%); 1.0 | ||||
Metropolitan region | 247 (34.8%) | 190 (76.9%); 1.13 (1.02-1.25) | 0.016 | 166 (67.2%); 1.22 (1.07-1.39) | 0.003 | 126 (51.0%); 1.33 (1.11-1.60) | 0.002 | 81 (64.3%); 1.58 (1.23-2.04) | 0 |
Countryside | 134 (18.9%) | 118 (88.1%); 1.29 (1.17-1.43) | 0 | 112 (83.6%); 1.52 (1.34-1.72) | 0 | 91 (67.9%); 1.77 (1.48-2.13) | 0 | 68 (74.7%); 1.84 (1.44-2.36) | 0 |
Follow-up site | |||||||||
HNSC | 341 (48.1%) | 320 (93.8%); 1.61 (1.47-1.76) | 0 | 340 (99.7%); 3.03 (2.62-3.50) | 0 | 237 (69.5%); 2.39 (2.00-2.84) | 0 | 166 (70.0%); 1.97 (1.50-2.58) | 0 |
External | 121 (17.1%) | 214 (58.2%); 1.0 | 121 (32.9%); 1.0 | 107 (29.1%); 1.0 | 38 (35.5%); 1.0 | ||||
Institutionalized | |||||||||
Yes | 33 (4.7%) | 25 (75.8%); 1.0 | 18 (54.5%); 1.0 | 12 (36.4%); 0.74 (0.46-1.17) | 0.198 | 8 (66.7%); 1.12 (0.74-1.70) | |||
No | 676 (95.3%) | 509 (75.3%); 1.00 (0.82-1.22) | 0.952 | 443 (65.5%); 0.83 (0.60-1.14) | 0.255 | 332 (49.1%); 1.0 | 196 (59.0%); 1.0 | 0.561 | |
Co-infection with HBV | |||||||||
Yes | 73 (10.3%) | 61 (83.6%); 1.12 (1.00-1.25) | 0.041 | 43 (58.9%); 1.0 | 30 (41.1%); 0.83 (0.62-1.10) | 0.208 | 18 (60.0%); 1.01 (0.74-1.37) | 0.935 | |
No | 636 (89.7%) | 473 (74.4%); 1.0 | 418 (65.7%); 0.89 (0.73-1.09) | 0.282 | 314 (49.4%); 1.0 | 186 (59.2%); 1.0 | 0.935 | ||
Co-infection with HIV | |||||||||
Yes | 93 (13.1%) | 75 (80.6%); 1.08 (0.97-1.20) | 0.158 | 63 (67.7%); 1.04 (0.90-1.22) | 0.541 | 35 (37.6%); 0.75 (0.57-0.98) | 0.039 | 17 (48.6%); 0.80 (0.56-1.14) | 0.222 |
No | 616 (86.9%) | 459 (74.5%); 1.08 | 398 (64.6%); 1.0 | 309 (50.2%); 1.0 | 187 (60.5%); 1.0 | ||||
Cirrhosis | |||||||||
Yes | 126 (17.8%) | 112 (88.9%); 1.22 (1.13-1.33) | 0 | 106 (84.1%); 1.38 (1.25-1.52) | 0 | 82 (65.1%); 1.44 (1.23-1.69) | 0 | 60 (73.2%); 1.33 (1.12-1.57) | 0.001 |
No | 583 (82.2%) | 422 (72.4%); 1.0 | 355 (60.9%); 1.0 | 262 (44.9%); 1.0 | 144 (55.0%); 1.0 | ||||
Date of diagnosis | |||||||||
2015 | 149 (21.0%) | 111 (74.5%); 1.0 | 102 (68.5%); 1.0 | 76 (51%); 1.0 | 42 (55.3%); 1.0 | ||||
2016 | 136 (19.2%) | 113 (83.1%); 1.11 (0.98-1.25) | 0.076 | 101 (74.3%); 1.08 (0.93-1.25) | 0.278 | 72 (52.9%); 1.03 (0.83-1.29) | 0.744 | 51 (70.8%); 1.28 (0.99-1.64) | 0.052 |
2017 | 121 (17.1%) | 92 (76.0%); 1.02 (0.89-1.17) | 0.771 | 84 (69.4%); 1.01 (0.86-1.19) | 0.865 | 68 (56.2%); 1.10 (0.88-1.37) | 0.393 | 45 (66.2%); 1.19 (0.91-1.56) | 0.181 |
2018 | 121 (17.1%) | 80 (66.1%); 0.88 (0.75-1.04) | 0.140 | 72 (59.5%); 0.86 (0.72-1.04) | 0.133 | 53 (43.8%); 0.85 (0.66-1.10) | 0.244 | 30 (56.6%); 1.04 (0.75-1.39) | 0.880 |
2019 | 128 (18.1%) | 90 (70.3%); 0.94 (0.81-1.09) | 0.440 | 67 (52.3%); 0.76 (0.62-0.93) | 0.008 | 49 (38.3%); 0.75 (0.57-0.98) | 0.038 | 22 (44.9%); 0.81 (0.56-1.17) | 0.272 |
2020 | 54 (7.6%) | 48 (88.9%); 1.19 (1.04-1.36) | 0.009 | 35 (64.8%); 0.94 (0.75-1.18) | 0.634 | 26 (48.1%); 0.94 (0.68-1.29) | 0.723 | 14 (53.8%); 0.97 (0.64-1.46) | 0.901 |
- Citation: Vaucher MB, Silva CU, Varella IRS, Kim AYS, Kliemann DA. Stages of care for patients with chronic hepatitis C at a hospital in southern Brazil. World J Hepatol 2023; 15(8): 973-984
- URL: https://www.wjgnet.com/1948-5182/full/v15/i8/973.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i8.973